




An innovative company dedicated to developing products and technologies that utilize molecular hydrogen for the MedTech and HealthTech industries.

## ALZHEIMER'S DISEASE: KEY PROJECT

- One of the most common forms of dementia (60-70% of cases).
- Since 2008, an international consortium of pharmaceutical companies has been searching for a solution.
- No causal treatment without side effects has been found yet.
- H2 Global Group's patented breakthrough: A side effect-free treatment and mitigation of Alzheimer's disease using molecular hydrogen.



## MARKET CHALLENGES



## Our know-how



- **Scientifically proven health effects of molecular hydrogen**  
A distinctive approach with a direct beneficial impact on human cells.
- **Molecular hydrogen**  
A bioactive substance with anti-inflammatory properties.  
A selective antioxidant with no side effects.  
A comprehensive product portfolio.
- **Patents and utility models**  
Alzheimer's disease – Patented in the EU, USA, Canada, Asian and Arab countries, and beyond.



## All-around product portfolio



## OUR OPPORTUNITIES AND BENEFITS



## Our patents and utility models


- Patents focused on therapy and reducing the impact of Alzheimer's disease.
- Innovative application tools for topical and transdermal hydrogen gas therapy, supporting body regeneration.
- Specialised application aids designed for the treatment and regeneration of the ears, eyes, and oral cavity.

## STRATEGIC GOALS

- ✓ Validation of pilot study results through extensive clinical testing.
- ✓ Development of innovative products registered as medical devices for use in healthcare facilities.
- ✓ Expanding our reach into global markets.
- ✓ Establishing a strong foothold in both B2B and B2C segments through strategic partnerships and international collaborations.

## MARKET POTENTIAL

Estimated growth of the MedTech and HealthTech market.



## INVESTMENT STRATEGY

The investment strategy encompasses the development and certification of medical technologies, business expansion, acquisitions of distribution and manufacturing companies, and cost optimization to maximize efficiency.



### Two key pillars

- Development of medical technologies (MedTech)
- Commercial trade and global expansion



### Strategic investment activities

- Exit strategy
- Investing in production self-sufficiency and distribution net
- H2 Invest – Hydrogen Fund




## Financial strategy

The projected sales growth is driven by the planned registration of medical devices, a strong foothold in the Czech market, and expansion into international markets.

The year 2025 is expected to be a turning point, with the company achieving a moderate profit at the EBITDA level. If financial plan projections are met, EBITDA margin profitability is set to reach 18.0% by 2028.

## COMPANY REVENUES 2023-2028 (USD million)



To achieve the planned growth, ongoing investor funding is essential — particularly for securing medical registrations and expanding into key international markets.